Tag

Trem2

All articles tagged with #trem2

business23 days ago•1 min saved

Novartis exits ALS program after phase 2 setback

Novartis has halted its ALS program for VHB937/lifonebart after a phase 2 trial failed to meet primary and secondary endpoints in 251 early-stage ALS patients. While TREM2 remains a target of interest for neurodegenerative diseases, the trial's negative result undermines ALS prospects for the drug and led the company to discontinue ALS development, though the candidate continues to enroll in Alzheimer’s trials. The setback, amid other recent R&D disappointments for Novartis, coincides with a strategic push into brain delivery technology via a $125 million Sironax deal to bolster neuroscience efforts.

via Fierce Biotech|

#als #business #novartis

business23 days ago•0 min saved

Novartis ends ALS program after Phase 2 TREM2 trial setback

Novartis has scrapped development of its Phase 2 ALS candidate targeting TREM2 after disappointing trial results, effectively ending the program, according to Endpoints News.

via Endpoints News|

#als #business #drug-development

science1 month ago•3 min saved

Protective Brain Microglia Rise with Alzheimer's Progression, Study Finds

An unprecedented analysis of over 830,000 brain immune cells from 1,607 donors identified a disease-associated microglia subtype that expands as Alzheimer's progresses and relies on the TREM2-MITF-GPNMB pathway to clear harmful material, suggesting therapies should bolster the brain’s natural immune defenses rather than focus solely on amyloid plaques.

via Neuroscience News|

#alzheimers-disease #brain-immunity #microglia

science5 months ago•9 min saved

Eliminating senescent macrophages reverses fatty liver in mice

UCLA researchers identify a population of p21+ TREM2+ senescent macrophages that drive liver inflammation and fatty liver; removing them in mice on a fatty/high-cholesterol diet reverses liver damage and inflammation without changing diet, using the senolytic drug ABT-263. However, ABT-263 is too toxic for humans, so researchers are seeking safer therapies, and human liver data show higher senescent macrophage signatures in diseased livers, suggesting potential relevance to people and other aging-related diseases.

via SciTechDaily|

#aging #fatty-liver-disease #p21

science5 months ago•98 min saved

p21+TREM2+ Senescent Macrophages Drive Inflammaging and MASLD, Reversed by Senolytics

A Nature Aging study identifies a distinct population of p21+ Trem2+ senescent macrophages as major drivers of inflammaging. These cells exhibit a SASP and type I interferon signaling driven in part by cytosolic mitochondrial DNA, accumulate in aging livers and in metabolic dysfunction-associated steatotic liver disease (MASLD), and are distinct from classic M1/M2 macrophages. In both mouse models and human tissue, senolytic treatment with ABT-263 reduces liver inflammation and steatosis, supporting macrophage senescence as a tractable target for aging-related liver disease.

via Nature|

#inflammaging #masld #p21

science8 months ago•2 min saved

Cancer Protein May Unlock a New Avenue for Alzheimer’s Treatment

In a mouse study, tumors produced the protein cystatin-C, which traveled to the brain, bound toxic amyloid oligomers, and activated microglia via the TREM2 receptor to clear plaques, improving cognitive tasks. While promising as a novel research path beyond amyloid-lowering strategies, whether these effects translate to humans remains unknown and more work is needed; the study warns against pursuing cancer as a therapy and emphasizes early-stage findings.

via Gizmodo|

#alzheimers #cancer #cystatin-c